Topical Treatment with Glucocorticoids

  • M. Kerscher
  • S. Williams
  • P. Lehmann
Chapter

Keywords

Atopic Dermatitis Topical Corticosteroid Allergic Contact Dermatitis Mometasone Furoate Tacrolimus Ointment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akers W (1980) Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 116:786–788CrossRefPubMedGoogle Scholar
  2. 2.
    Arima Y, Nakai Y, Hayakawa R, Nishino T (2003) Antibacterial effect of beta-thujaplicin on staphylococci isolated from atopic dermatitis: relationship between changes in the number of viable bacterial cells and clinical improvement in an eczematous lesion of atopic dermatitis. J Anti microb Chemother 51:113–122Google Scholar
  3. 3.
    Bandmann HJ, Huber-Riffeser G, Woyton A (1966) Kontaktallergie gegen Triamcinolonacetonid. Hautarzt 17:183–185PubMedGoogle Scholar
  4. 4.
    Bork K (1985) Kutane Arzneimittelnebenwirkungen. Schattauer, StuttgartGoogle Scholar
  5. 5.
    Burckhardt W(1959) Kontakekzem durch Hydrocortison. Hautarzt 10:42–43Google Scholar
  6. 6.
    Calnan CD (1976) Use and abuse topical steroids. Dermatologica 152[Suppl 1]:247–251PubMedGoogle Scholar
  7. 7.
    Carruthers JA, August PJ, Stoughton RCS (1975) Observations on the systemic effect of topical clobetasol propionate (Dermovate). BMJ 4:203–204PubMedGoogle Scholar
  8. 8.
    Church R (1969) Sensitivity to hydrocortisone acetate ointment. Br J Dermatol 72:431–444Google Scholar
  9. 9.
    Cornell RC, Stoughton RB (1985) Topical corticosteroids: guidelines of therapy. Hoechst (Hoechst medication update)Google Scholar
  10. 10.
    Deffer TA, Goette DK (1987) Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 123: 571–572CrossRefPubMedGoogle Scholar
  11. 11.
    Dooms-Goossens A, Vanhee J, Vanderheyden D, Gevers D, Willems L, Degreef H (1983) Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasol butyrate. Contact Dermatitis 9:470–478i]PubMedGoogle Scholar
  12. 12.
    Dooms-Goossens A (1988) Identification of undetected corticosteroid allergy. Contact Dermatitits 18:124–125Google Scholar
  13. 13.
    Dooms-Goossens A, Degreef H, Coopmann S (1989) Corticosteroid contact allergy: a reality. In: Frosch PJ, Dooms-Goossens A, Lachapell JM, Rycroft RJG. Scheper RJ (eds) Current topics in contact dermatitis. Springer, Berlin Heidelberg New York, pp 233–237Google Scholar
  14. 14.
    Du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111:581–583PubMedGoogle Scholar
  15. 15.
    Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M (2002) Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46:495–504CrossRefPubMedGoogle Scholar
  16. 16.
    Faergemann J, Christensen O, Sjovall P, Johnsson A, Hersle K, Nordin P, Edmar B, Svensson A (2000) An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 14: 393–396CrossRefPubMedGoogle Scholar
  17. 17.
    Feldman RJ, Maibach HI (1967) Regional variation in percutaneous penetration of cortisol in man. J Invest Dermatol 48:181Google Scholar
  18. 18.
    Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D (2003) Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 207:15–21CrossRefPubMedGoogle Scholar
  19. 19.
    Gibson JR, Darley C, Kirsch J, Saihan EM, Neild VS (1982) The dilution of proprietary corticosteroid ointments — an attempt to evaluate relative clinical potencies. Br J Dermatol 106:445–447PubMedGoogle Scholar
  20. 20.
    Gille J (2002) Glukokortikoide. In: Zollner TM, Boehncke WH, Kaufmann R (eds) Atopische Dermatitis. Blackwell Wissenschaftsverlag Berlin, pp 115–125Google Scholar
  21. 21.
    Gloor M, Hauth A, Gehring W (2003) O/W emulsions compromise the stratum corneum barrier and improve drug penetration. Pharmazie 58:709–715PubMedGoogle Scholar
  22. 22.
    Gormar FE, Bernd A, Holzmann H (1990) The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro. Arzneimittelforschung 40:192–196PubMedGoogle Scholar
  23. 23.
    Goulding NJ, Flower RJ (2001) Glucocorticoid biology — a molecular maze and clinical challenge. In: Goulding NJ, Flower RJ (eds) Glucocorticoids. Birkhäuser-Verlag BaselGoogle Scholar
  24. 24.
    Guy RH, Maibach HI (1985) Calculations of body exposure from percutaneous absorption data. In: Bonaugh RL, Maibach HI (eds) Percutaneous absorption. Dekker, New York, pp 461–466Google Scholar
  25. 25.
    Hackemüller D (1988) Einfluß von Feuchthaltemitteln auf Hautmodelle und Wirkstoffpenetration in vivo. Thesis, University Düsseldorf, GermanyGoogle Scholar
  26. 26.
    Haggenmüller F (1993) Irrationale Kortisonangst. Fortschr Med 111:359PubMedGoogle Scholar
  27. 27.
    Hardman JG, Limbird LE, Goodmann, Gilman A (2001) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 1655–1801Google Scholar
  28. 28.
    Hatz HJ (1998) Glucocorticoide. Immunologische Grundlagen, Pharmakologie und Therapierichtlinien. Medizinisch-pharmakologisches Kompendium. Vol. 12. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 603–628Google Scholar
  29. 29.
    Hausen BM, Kulenkamp D (1985) Kontakallergie auf Fludroxycortid und Cetylalkohol. Dermatosen 33:27–28Google Scholar
  30. 30.
    Hausen BM, Foussereau J (1987) The sensitizing capacity of tixocortol pivalate. Contact Dermatitis 17:63–64Google Scholar
  31. 31.
    Hein R, Korting HC, Mehring T (1994) Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 7:300–306PubMedGoogle Scholar
  32. 32.
    Hench PS, Kendall EC, Slocumb CH, Polley HF (1949) The effect of a hormone of the adrenal cortex 17-hydroxy-11-dehydrocorticosterone (compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24:181–197Google Scholar
  33. 33.
    Hepburn DJ, Aeling JL, Weston WL (1996) A reappraisal of topical steroid potency. Pediatr Dermatol 13:239–245PubMedGoogle Scholar
  34. 34.
    Higuchi T (1960) Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11:85–97Google Scholar
  35. 35.
    Kaiser H, Kley HK (2002) Cortisontherapie: Corticoide in Klinik und Praxis, 11th edn. Thieme, StuttgartGoogle Scholar
  36. 36.
    Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA (1989) Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential. Int J Dermatol 28:342–344PubMedGoogle Scholar
  37. 37.
    Kecskes A, Heger-Mahn D, Kuhlmann RK, Lange L (1993) Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointmentswith equal antiinflammatory activity. J Am Acad Dermatol 29:576–580PubMedGoogle Scholar
  38. 38.
    Kelly JW, Cains GD, Rallings M, Gilmore SJ (1991) Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol 32:85–91PubMedGoogle Scholar
  39. 39.
    Kerscher MJ, Korting HC (1992) Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol 72:214–216PubMedGoogle Scholar
  40. 40.
    Kerscher MJ, Hart H, Korting HC, Stalleicken D (1995) In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 33:187–189PubMedGoogle Scholar
  41. 41.
    Kooij R (1959) Hypersensitivity to hydrocortisone. Br J Dermatol 71:392–394PubMedGoogle Scholar
  42. 42.
    Korting HC, Kerscher MJ, Schafer-Korting M (1992) Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 27:87–92PubMedGoogle Scholar
  43. 43.
    Korting HC, Vieluf D, Kerscher M (1992) 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 42:159–161CrossRefPubMedGoogle Scholar
  44. 44.
    Lepoittevin JP, Drieghe J, Dooms-Goossens A (1995) Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 131:31–37CrossRefPubMedGoogle Scholar
  45. 45.
    Lever R, Hadley K, Downey D, McKie R (1988) Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 119:189–198PubMedGoogle Scholar
  46. 46.
    Lippold BC (1984) Biopharmazie, 2nd edn. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  47. 47.
    Lippold BC (1984) Selection of the vehicle for topical administration of drugs. Pharm Acta Helv 59:166–171PubMedGoogle Scholar
  48. 48.
    Lippold BC, Schneemann H (1984) The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution and suspension type ointment. Int J Pharm (Amst) 22:31–43Google Scholar
  49. 49.
    Maibach HI (1976) In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 152[Suppl 1]:11–25PubMedGoogle Scholar
  50. 50.
    Malzfeldt E (1988) KlinischeWirksamkeit von Betamethason-17-benzoat-Salben in Abhängigkeit von der Wirkstofflöslichkeit in der Salbengrundlage. Thesis, University Düsseldorf, GermanyGoogle Scholar
  51. 51.
    Malzfeldt E, Lehmann P, Goerz G, Lippold BC (1989) Drug solubility in vehicle and efficacy of ointments. Arch Dermatol Res 281:193–197CrossRefPubMedGoogle Scholar
  52. 52.
    Maucher OM, Faber M, Knipper H, Kirchner S, Schöpf E (1987) Kortikoidallergie. Hautarzt 38:577–582PubMedGoogle Scholar
  53. 53.
    McKenzie AW, Stoughton RB (1962) Method for comparing percutaneous absorption of steroids. Arch Dermatol 88:608–611Google Scholar
  54. 54.
    Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M; CASM-DE-01 Study Group (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology 205:271–277CrossRefPubMedGoogle Scholar
  55. 55.
    Meurer M, Wozel G (2003) Behandlung des atopischen Ekzems mit topischen Calcineurininhibitoren. Hautarzt 54:424–431PubMedGoogle Scholar
  56. 56.
    Niedner R, Ziegenmeyer J (1992) Dermatika: Therapeutischer Einsatz, Pharmakologie und Pharmazie. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  57. 57.
    Oberdisse E, Hackenthal E, Kuschinsky K (2002) Pharmakologie und Toxikologie, 3rd edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  58. 58.
    O’Hara JA (1962) Anaphylactic reactions to hydrocortisone injections. BMJ 1:615Google Scholar
  59. 59.
    Oleffe JA, Blondeel A, de Coninck A (1979) Allergy to chlorocresol and propylene glycol in a steroid cream. Contact Dermatitis 5:53–54PubMedGoogle Scholar
  60. 60.
    Ostrenga J, Steinmetz C, Poulsen B (1971) Significance of vehicle composition I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 60:1175–1179PubMedGoogle Scholar
  61. 61.
    Petro W (1991) Cortisonangst der Patienten. Haut 3:53Google Scholar
  62. 62.
    Polano MK, Ponec M (1976) Dependence of corticosteroid penetration on the vehicle. Arch Dermatol 112:675–680CrossRefPubMedGoogle Scholar
  63. 63.
    Prakash A, Benfield P (1998) Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 55:145–163PubMedGoogle Scholar
  64. 64.
    Reitamo S, Lauerma AI, Stubb S, Käyhkö K, Visa K, Förström L (1986) Delayed hypersensitivity to topical corticosteroids. J Am Acad Dermatol 14:582–589PubMedGoogle Scholar
  65. 65.
    Reitamo S, Rustin M, Ruzicka T (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis: the European Tacrolimus Ointment Study Group. J Allergy Clin Immunol 109:547–555PubMedGoogle Scholar
  66. 66.
    Rote Liste (2004) Editio Cantor Verlag für Medizin und Naturwissenschaften, AulendorfGoogle Scholar
  67. 67.
    Ruzicka T, Assmann T, Homey B (1999) Tacrolimus — the drug for the turn of the century? Arch Dermatol 135:574–580CrossRefPubMedGoogle Scholar
  68. 68.
    Schäfer H, Zesch A, Stüttgen G (1982) Skin permeability. Springer, Berlin Heidelberg New YorkGoogle Scholar
  69. 69.
    Schäfer H, Zesch A, Schalla W, Stüttgen G (1984) Pharmakokinetik externer Glucocorticoide. Allergologie 3:194–198Google Scholar
  70. 70.
    Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S (1993) Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 54:448–456PubMedGoogle Scholar
  71. 71.
    Schalla W (1985) Lokaltherapiemit Kortikoiden. Z Hautkr 60:609–618PubMedGoogle Scholar
  72. 72.
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283–286PubMedGoogle Scholar
  73. 73.
    Sears HW, Bailer JW, Yeadon A (1997) Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther 19:710–719CrossRefPubMedGoogle Scholar
  74. 74.
    Sönnichsen N (1962) Beitrag zur Hypercortison-Überempfindlichkeit. Hautarzt 13:226–227Google Scholar
  75. 75.
    Stierstorfer MB, Baughman RD (1988) Photosensitivity to desoximetasone emollient cream. Arch Dermatol 124: 1870–1871CrossRefPubMedGoogle Scholar
  76. 76.
    Stoppoloni G, Prisco F, Santinelli R, Sicuranza C, Giordano C (1983) Potential hazards of topical steroid therapy. Am J Dis Child 137:1130–1131PubMedGoogle Scholar
  77. 77.
    Stoughton RB (1987) Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 123:1312–1314CrossRefPubMedGoogle Scholar
  78. 78.
    Sulzberger MB, Witten VH (1952) The effect of topically applied compound E in selected dermatoses. J Invest Dermatol 19:101–102PubMedGoogle Scholar
  79. 79.
    Thaci D (2003) Langzeitmanagement des atopischen Ekzems bei Kindern mit Calcineurininhibitoren. Hautarzt 54:418–423PubMedGoogle Scholar
  80. 80.
    Tsuij T, Kayoda A, Tanaka R, Kono T, Hamada T (1986) Milia induced by corticosteroids. Arch Dermatol 122:139–140Google Scholar
  81. 81.
    Vernon HJ, Lane AT, Weston W (1991) Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 24:603–607PubMedGoogle Scholar
  82. 82.
    Wachs GN, Maibach HI (1976) Co-operative double-blind trial of an antibiotic corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 95:323–328PubMedGoogle Scholar
  83. 83.
    Wahn U, Bos JD, Goodfield M et al. (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2CrossRefPubMedGoogle Scholar
  84. 84.
    Watson WS, Findlay AY (1988) The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol-17-propionate in vivo. Br J Dermatol 118:523–530PubMedGoogle Scholar
  85. 85.
    Wehling M (1994) Non-genomic steroid effects. Trends Endocrinol Metab 5:347Google Scholar
  86. 86.
    Wendt H, Frosch PJ (1982) Klinisch-pharmakologische Modelle zur Prüfung von Corticoidexterna. Kerger, BaselGoogle Scholar
  87. 87.
    Zaun H, Altmeyer P (1973) Ergebnisse refleksphotometrischer Bestimmungen der Vasoconstriktion nach topischer Steroidapplikation. Arch Dermatol Forsch 247:379–386PubMedGoogle Scholar
  88. 88.
    Zellweger JP, Andershub HP, Holzer C, Weber H (1994) Welches Image hat das Cortison? Ars Medici 84:231Google Scholar
  89. 89.
    Zürcher K, Krebs A (1980) Hautnebenwirkungen interner Arzneimittel. Karger, BaselGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • M. Kerscher
  • S. Williams
  • P. Lehmann

There are no affiliations available

Personalised recommendations